U.S. Markets open in 4 hrs 20 mins

China Biologic Products Holdings, Inc. (CBPO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
111.14+0.55 (+0.50%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close111.26
Bid0.00 x 800
Ask115.57 x 1200
Day's Range110.77 - 112.11
52 Week Range97.91 - 119.44
Avg. Volume101,409
Market Cap4.288B
Beta (5Y Monthly)0.67
PE Ratio (TTM)29.32
EPS (TTM)3.79
Earnings DateNov 11, 2020 - Nov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est101.78
  • China Biologic Products Inc (CBPO) Q2 2020 Earnings Call Transcript
    Motley Fool

    China Biologic Products Inc (CBPO) Q2 2020 Earnings Call Transcript

    An earnings release is available on the Company's website. Today, you will hear from China Biologic's Chairman and CEO, Mr. Joseph Chow, who will start off the call with a review of the Company's operating results and report recent developments. China Biologic's CFO, Mr. Ming Yang, will be available during the Q&A section following the prepared remarks.

  • China Biologic Reports Financial Results for the Second Quarter of 2020
    PR Newswire

    China Biologic Reports Financial Results for the Second Quarter of 2020

    China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarter of 2020.

  • The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs

    The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs

    Biotech stocks came under pressure in the week ended Aug. 14 amid mixed earnings news flow from the sector. FDA decisions scheduled for the week also produced adverse outcomes. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) and Fennec Pharmaceuticals Inc (NASDAQ: FENC) received complete response letters for their respective regulatory applications, while a decision on Eton Pharmaceuticals Inc's (NASDAQ: ETON) eye inflammation drug hadn't come by the Aug. 10 decision date.The week, however, saw a signing spree by coronavirus vaccine developers, which stitched up manufacturing as well as supply deals.Here are the key catalysts for the unfolding week.ConferencesVirtual Keystone Symposia: Advances in Cancer Immunotherapy: Aug. 17-19PDUFA DatesGilead Sciences, Inc. (NASDAQ: GILD) and licensing partner GALAPAGOS NV/S ADR (NASDAQ: GLPG) await FDA decision on the NDA for filgotinib in moderate-to-severe rheumatoid arthritis. (estimated date of Wednesday, Aug. 19, assuming priority review)The FDA is set to rule on BioMarin Pharmaceutical Inc.'s (NASDAQ: BMRN) BLA for valoctocogene roxaparvovec, its investigational AAV5 gene therapy for treating adults with hemophilia A. (Friday)Tricida Inc (NASDAQ: TCDA) has a Aug. 22 PDUFA date for the NDA for its TRC 101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease. With FDA's communication to the company in mid-July, stating that it has identified deficiencies in the application, it is less likely the investigational drug is approved by the D-day. (Saturday)See also: Genoskin Offers Live Skin Models To Bridge Animal, Human Testing: 'The Market Opportunity Is Huge'View more earnings on IBBEarningsMonday Milestone Scientific Inc. (NYSE: MLSS) (before the market open) China Biologic Products Holdings Inc (NASDAQ: CBPO) (after the close) Precipio Inc (NASDAQ: PRPO) (after the close)Tuesday ADC Therapeutics SA (NYSE: ADCT) (before the market open) PAVmed Inc (NASDAQ: PAVM) (after the close) Supernus Pharmaceuticals Inc (NASDAQ: SUPN) (after the close)IPOsLa Jolla, California-based InhibRx, a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, with particular focus on oncology, has filed with the SEC to offer 6 million shares of its common stock at an estimated price range of $16-$18. The company said in the filing it has applied to list its shares on the Nasdaq under the ticker symbol INBX.Harmony Biosciences Holdings Inc, a Plymouth, Pennsylvania-based commercial-stage pharmaceutical company focused on innovative therapies for patients living with rare neurological disorders, has filed with the SEC to offer 4.651 million shares of its common stock. The estimated price range for the offering is $20-$23. The company has applied for listing its shares on the Nasdaq under the ticker symbol HRMY.IPO Quiet Period ExpiryNurix Therapeutics Inc (NASDAQ: NRIX) iTeos Therapeutics Inc (NASDAQ: ITOS) Inozyme Pharma Inc (NASDAQ: INZY) Annexon Inc (NASDAQ: ANNX)Related Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates See more from Benzinga * The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal * The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller * The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.